{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=45&q=hormone+receptor-positive", "query": { "q": "hormone receptor-positive", "condition": "Breast Cancer", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 679, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=46&q=hormone+receptor-positive&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer&page=44&q=hormone+receptor-positive&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T15:23:23.706Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03134638", "title": "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Ovarian Cancer", "Breast Cancer" ], "interventions": [ { "name": "SY-1365 (Part 1)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "SY-1365 (Cohort 2)", "type": "DRUG" }, { "name": "SY-1365 (Cohort 5)", "type": "DRUG" }, { "name": "SY-1365 (Part 2 Single Agent)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syros Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2017-05-12", "completion_date": "2020-06-24", "has_results": false, "last_update_posted_date": "2021-03-09", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Francisco, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03134638" }, { "nct_id": "NCT05323955", "title": "Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases", "Human Epidermal Growth Factor 2 Positive Carcinoma of Breast", "Advanced Breast Cancer" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab Emtansine (T-DM1)", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carey Anders, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2023-03-23", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 8, "location_summary": "San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05323955" }, { "nct_id": "NCT00958971", "title": "Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "TKI258", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 43, "start_date": "2009-07", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 18, "location_summary": "Bakersfield, California • Beverly Hills, California • Los Angeles, California + 13 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redondo Beach", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00958971" }, { "nct_id": "NCT00602043", "title": "F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "Progesterone Receptor-negative Breast Cancer", "Progesterone Receptor-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "F-18 16 alpha-fluoroestradiol", "type": "RADIATION" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2008-09", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2020-02-19", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00602043" }, { "nct_id": "NCT04314401", "title": "National Cancer Institute \"Cancer Moonshot Biobank\"", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukemia", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Esophageal Carcinoma", "Fallopian Tube Carcinoma", "Gastric Carcinoma", "Hormone Receptor-Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Lung Non-Small Cell Carcinoma", "Lung Small Cell Carcinoma", "Malignant Solid Neoplasm", "Melanoma", "Metastatic Prostate Carcinoma", "Multiple Myeloma", "Ovarian Carcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Primary Peritoneal Carcinoma", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Paracentesis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 1600, "start_date": "2020-11-11", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 147, "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Kingman", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04314401" }, { "nct_id": "NCT01708161", "title": "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PIK3CA Mutated Advanced Solid Tumors", "PIK3CA Amplified Advanced Solid Tumors" ], "interventions": [ { "name": "BYL719", "type": "DRUG" }, { "name": "AMG 479", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2012-11-27", "completion_date": "2017-06-01", "has_results": true, "last_update_posted_date": "2018-09-13", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01708161" }, { "nct_id": "NCT00696072", "title": "Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2008-08", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 27, "location_summary": "Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Hudson", "state": "Florida" }, { "city": "Carmel", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00696072" }, { "nct_id": "NCT02049957", "title": "Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 118, "start_date": "2014-02-13", "completion_date": "2018-06-29", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 30, "location_summary": "Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02049957" }, { "nct_id": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancers", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer", "Head and Neck Squamous-Cell Carcinoma", "Platinum Resistant High Grade Epithelial Ovarian Cancer" ], "interventions": [ { "name": "ABBV-400", "type": "DRUG" }, { "name": "Itraconazole (ITZ)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2023-11-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 20, "location_summary": "Duarte, California • San Francisco, California • Aurora, Colorado + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06084481" }, { "nct_id": "NCT04906395", "title": "Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "TOL2506", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole Tablets", "type": "DRUG" }, { "name": "Anastrozole Tablets", "type": "DRUG" }, { "name": "Exemestane Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tolmar Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 250, "start_date": "2021-07-01", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-20T15:23:23.706Z", "location_count": 17, "location_summary": "Greenbrae, California • Parker, Colorado • Chicago, Illinois + 14 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Parker", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Glenn Dale", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906395" } ] }